.png "Robert Fuhlbrigge, MD, PhD photo")
University of Colorado
Denver, CO, United States
Dr. Fuhlbrigge received his M.D. and Ph.D. in Immunology from Washington University- St. Louis and completed his residency in Pediatrics at St. Louis Children’s Hospital. He received clinical fellowship training in Pediatric Rheumatology at Northwick Park and Great Ormond Street Hospitals, London UK. He completed his fellowship at Boston Children’s Hospital and joined the faculty of Harvard Medical School and the Division of Immunology at Boston Children’s in 1995. During his tenure at Harvard, Dr. Fuhlbrigge served as Director of Research in Rheumatology at Boston Children’s Hospital, and as Vice Chair for Research in the Department of Dermatology at Brigham and Women’s Hospital. Dr. Fuhlbrigge joined the faculty at the University of Colorado School of Medicine in 2016 as Professor of Pediatrics with Tenure and Section Head for Pediatric Rheumatology at the School of Medicine and Chair of Rheumatology at Children’s Hospital Colorado. Dr. Fuhlbrigge remains active in research, exploring mechanisms of leukocyte homing and the regulation of tissue specific inflammation, and sees patients in the ambulatory and inpatient services at Children’s Hospital Colorado. He is a founding member, Past President and current member of the Board of Directors of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) and an active participant in this member-driven network dedicated to collaborative research to prevent, treat and cure pediatric rheumatic diseases.
Friday, November 10, 2023
3:45 PM – 4:05 PM PT
Disclosure(s): No financial relationships with ineligible companies to disclose
Friday, November 10, 2023
4:05 PM – 4:25 PM PT
Disclosure(s): No financial relationships with ineligible companies to disclose
Friday, November 10, 2023
4:25 PM – 4:45 PM PT
Disclosure(s): No financial relationships with ineligible companies to disclose
Friday, November 10, 2023
4:45 PM – 5:05 PM PT
Disclosure(s): No financial relationships with ineligible companies to disclose
Friday, November 10, 2023
5:05 PM – 5:25 PM PT
Disclosure(s): No financial relationships with ineligible companies to disclose
